At a glance
- Originator Hebrew University of Jerusalem
- Developer Purple Biotech; TyrNovo
- Class Antineoplastics; Small molecules
- Mechanism of Action Insulin receptor substrate protein inhibitors; STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Colorectal cancer; Solid tumours; Squamous cell cancer
- Preclinical Malignant melanoma
Most Recent Events
- 19 Apr 2024 Purple Biotech plans a phase II trial in Squamous cell cancer and Colorectal cancer (Recurrent, Metastatic disease, Combination therapy) in the first half of 2024 (Purple Biotech pipeline, April 2024)
- 27 Feb 2024 Updated efficacy, adverse events and pharmacokinetics data from a phase I/II trial in Squamous cell cancer, Solid tumours and Colorectal cancer presented at the European Society of Medical Oncology Targeted Anticancer Therapies Congress 2024 (ESMO TAT-2024)
- 26 Feb 2024 Efficacy, adverse events and pharmacokinetics data from a phase I/II trial in Squamous cell cancer presented at the European Society of Medical Oncology Targeted Anticancer Therapies Congress 2024 (ESMO TAT-2024)